Citadel Securities Maintains an 'Edge Negative' on Celgene (CELG); Behind the Smoke and Mirrors: Revlimid Ex-U.S. Growth Updated Guidance Suggests Slowdown Ahead
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Price: $108.24 --0%
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Citadel Securities maintains an 'Edge Negative' on Celgene (NASDAQ: CELG) price target of $47.
Citadel analyst says, "We are maintaining our Edge Negative Rating and 12-month $47 price target based on our expectation for a near-term deceleration in Revlimid revenue growth. We are updating our model to reflect increased ex-U.S. Abraxane revenues, offset by slowing ex-U.S. Revlimid revenue growth and higher operating expenses and a higher tax rate. Our FY revenue estimate increases to $4,607.9MM from $4,540.3MM, and our adjusted EPS estimate increases to $3.47 from $3.36."
For more ratings news on Celgene click here and for the rating history of Celgene click here.
Shares of Celgene closed at $59.48 yesterday.
Citadel analyst says, "We are maintaining our Edge Negative Rating and 12-month $47 price target based on our expectation for a near-term deceleration in Revlimid revenue growth. We are updating our model to reflect increased ex-U.S. Abraxane revenues, offset by slowing ex-U.S. Revlimid revenue growth and higher operating expenses and a higher tax rate. Our FY revenue estimate increases to $4,607.9MM from $4,540.3MM, and our adjusted EPS estimate increases to $3.47 from $3.36."
For more ratings news on Celgene click here and for the rating history of Celgene click here.
Shares of Celgene closed at $59.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
